Joel Baglole

Joel Baglole

InvestorPlace Contributor

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

Buy AT&T Stock as the Company’s Fortunes Improve

By Joel Baglole, InvestorPlace Contributor

AT&T's latest quarterly results show that the telecom giant has turned a corner, making T stock worth buying at its current levels.

Blackberry’s Time Has Passed. Stay Away From BB Stock.

By Joel Baglole, InvestorPlace Contributor

The one-time giant of the tech world likes to say it is more than a meme stock, but its finances and outlook say otherwise. Avoid BB stock.

5 Top Value Stocks Reviewed: 3 to Buy, 2 to Skip

By Joel Baglole, InvestorPlace Contributor

Value stocks that are trading at a lower price and destined to rise can bring strong returns. But not every discounted stock is a buy.

5 Important Stocks to Watch Right Now… and Why

By Joel Baglole, InvestorPlace Contributor

Some stocks are so influential that they demand to be on every investor's watchlist. These are market moving companies that impact us all.

Clover Health Is Either Cursed or Unlucky, but It’s Not a Buy Now

By Joel Baglole, InvestorPlace Contributor

Is healthcare insurer Clover Health Investments more than a meme stock? This is the question that both professional and retail investors are trying to answer after CLOV stock was targeted in late May by the meme stock crowd that congregates on the WallStreetBets Reddit forum. Clover Health has to convince investors that it is more than a flash in the pan meme stock and that its shares are worthy of sustained gains.

Load More